Opthea Ltd — Board/Management Information 2013

Dec 2, 2013

==> picture [211 x 55] intentionally omitted <==

ASX / Media Release

3 December 2013

CIRCADIAN CEO AND BOARD CHANGES

The Board of Directors of Circadian Technologies Limited (ASX:CIR) advises that Mr Robert Klupacs will step down from his roles as Chief Executive Officer and Managing Director effective today.

Ms Dominique Fisher (Chairman) will assume the role of interim Executive Director and Chairman to oversee the transition of Mr Klupacs’ duties, including oversight of capital management.

The Company continues to focus on its two subsidiary businesses - Opthea Pty Ltd under the leadership of Dr Megan Baldwin (CEO of Opthea) and Ceres Oncology Pty Ltd under the leadership of Dr Ian Leitch (Director, Clinical Research).

The Company is also pleased to announce the appointment of Dr Russell Howard as a Non-Executive Director. Dr Howard has acted as a special advisor to the Board of Directors since 2012. He offers invaluable experience having dedicated his career to life sciences and biotechnology.

Dr Howard is Executive Chairman at Neuclone, a Sydney company developing bio-similar monoclonal antibody drugs. He is also the Founder and CEO of Oakbio, a biotechnology company based in California, developing breakthrough sustainable microbe-based technologies that convert CO2 in waste gas into valuable chemical products.

Previously, Dr Howard was Founder and CEO of Maxygen, President & Scientific Director at Affymax and he also previously served on advisory panels for WHO and USAID.

Media enquiries

Sue Cato (02) 8306 4244

About Circadian Technologies Limited

Circadian (ASX:CIR; OTCQX:CKDXY)) is a biologics drug developer focusing on cancer, cancer related and ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian’s internal product development programs are primarily focused on developing VGX-100 (a human antibody against VEGF-C) as a treatment for lymphedema resulting from breast cancer treatment and solid tumours, in particular glioblastoma and colorectal cancer, as well as developing VGX-300 (soluble VEGFR-3) for ‘back of the eye’ disease such as wet Age Related Macular Degeneration. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.

Suite 0403 Level 4 650 Chapel Street South Yarra Victoria 3141 Australia T +61 (3) 9826 0399 F +61 (3) 9824 0083 www.circadian.com.au

ABN 32 006 340 567